Liposomal Doxorubicin, Bevacizumab, and Everolimus in Patients With Locally Advanced TNBC With Tumors Predicted Insensitive to Standard Chemotherapy; A Moonshot Initiative
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Invasive Breast Carcinoma|Triple-Negative Breast Carcinoma
Interventions: BIOLOGICAL: Bevacizumab|DRUG: Everolimus|OTHER: Laboratory Biomarker Analysis|DRUG: Pegylated Liposomal Doxorubicin Hydrochloride
Sponsor: M.D. Anderson Cancer Center